Pacific Edge Limited · NZX:PEB
Pacific Edge — Investor Presentation (October 2017)
16 slides from Pacific Edge's investor presentation, Oct 11, 2017
Slide 1: Capital Raising Presentation
PACIFIC EDGE Cancer Diagnostic Company zy Capital Raising Presentation 11 October 2017
Slide 2: Disclaimer
DISCLAIMER Important Notice This presentation has been prepared by Pacific Edge Limited (PEL). Information of a general nature The information in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may requ
Slide 3: Disclaimer
DISCLAIMER Past performance Investors should note that past performance, including past share price performance, cannot be relied upon as an indicator of (and provides no guidance as to) future PEL performance, including future financial position or share price performance. Investment risk An invest
Slide 4: Focused on providing patients better, faster and less invasive diagnostic tests
At Pacific Edge we are focused on providing patients better, faster and less invasive diagnostic tests. Our number one priority is the effective implementation of our strategy in the markets we operate through continued strong growth in sales of the suite of Cxbladder products. Financially we are st
Slide 5: Context for Capital Raising
CONTEXT FOR CAPITAL RAISING Over the last 16 years, Pacific Edge has been working towards commercialisation of its non invasive bladder cancer tests The company has communicated to the market and been working towards a number of major milestones and expects to complete the last of those over the nex
Slide 6: Offer Terms
OFFER TERMS PURPOSE: Summary of Offer Terms: The purpose of the offer is to Offer size Approximately NZ$21.3m ensure Pacific Edge has sufficient capital available as Offer ratio 1-for-6 it targets cash flow Offer price NZ$0.32 per New Share breakeven in FY19 Offer price discount 26.6% discount to th
Slide 7: Recent Milestones
RECENT MILESTONES Significant Progress Achieved Pacific Edge 2017 | Capital Raising Presentation 7
Slide 8: FY17 Financials (12 months to March 2017)
FY17 FINANCIALS (12 MONTHS TO 31 MARCH 2017) 62% Uplift in Product Sales OPERATING REVENUE Positive growth in product sales from new and existing In the past four years, operating revenue has grown from NZ$145,000 to NZ$8.1 million customers, particularly in North America and New 9.5 Zealand 7.2 62%
Slide 9: Transformational Customers
TRANSFORMATIONAL CUSTOMERS Strong progress with key target customers VETERANS ADMINISTRATION KAISER PERMANENTE COMPLETED √ Signed Federal Supply Schedule Agreement COMPLETED √ Completion of large scale User Programme in first half (Feb 2016) and negotiated contract price for FY17 and positive analys
Slide 10: Other Markets
OTHER MARKETS Delivering results in Australia, New Zealand and South East Asia AUSTRALIA • Tolmar Australia - dedicated urology sales executives leveraging their existing networks • Targeting large hospitals as well as individual urologists. Now underway with large hospital in South Australia • Thre
Slide 11: Revenue Outlook and Drivers
REVENUE OUTLOOK AND DRIVERS FY18 Revenue Uplift Expected In Line With Annual Trends • United States: Remains the primary focus • New Zealand: Continue to grow uptake by large public healthcare providers MARKETS • Australia: Conversion of User Programmes and greater sales coverage. Focus is on large
Slide 12: Estimated Lab Throughput (FY18 and FY19)
ESTIMATED LAB THROUGHPUT (FY18 AND FY19) Over 23,000 tests estimated to be undertaken in FY19 FY15 Actual FY16 Actual FY17 Actual FY18 Estimate FY19 Estimate Our estimates are bottom-up estimates by customer account, aggregated by country to the total group level Total 3,910 8,348 11,246 ~15,800 ~23
Slide 13: Pacific Edge Test Throughput versus Cash Receipts
PACIFIC EDGE TEST THROUGHPUT VERSUS CASH RECEIPTS Break even targeted in FY19 Currently approximately 75% of throughput tests are billable. FY17 FY18 FY19 Actual Estimate Estimate This is expected to improve gradually as User Programmes are transitioned to commercial relationships (User Programme La
Slide 14: Cash Generation Sensitivity
CASH GENERATION SENSITIVITY Cash receipts impacted by key contract timing and other variables There are five main variables that can significantly impact the timing and quantum of Pacific Edge’s FY19 estimated annual cash receipts. These Movement in FY19 Estimated Annual Cash Receipts (NZ$m) sensiti
Slide 15: Cash Sufficiency Supported by Capital Raise
CASH SUFFICIENCY SUPPORTED BY CAPITAL RAISE $21.3m raised under this offer to support working capital while cash flow breakeven is targeted • As at 31 March 2017, Pacific Edge had NZ$14.6m of available cash • Over the first half of FY18 Pacific Edge is operating at an average monthly cash flow defic
Slide 16: Appendix: Notes to the Forecast
APPENDIX: NOTES TO THE FORECAST US revenue makes up approximately 90% of Pacific Edge’s total revenue and remains our focus US revenue makes up approximately 90% of REIMBURSEMENT AND PAYMENT PROCESS FOR CMS AND PRIVATE PAYERS Pacific Edge’s total revenue with two significant contributors: Centers Fo